Simon Quick Advisors LLC Acquires 4,518 Shares of Lam Research Corporation $LRCX

Simon Quick Advisors LLC boosted its holdings in Lam Research Corporation (NASDAQ:LRCX) by 40.3% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 15,730 shares of the semiconductor company’s stock after purchasing an additional 4,518 shares during the quarter. Simon Quick Advisors LLC’s holdings in Lam Research were worth $1,531,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in LRCX. Brighton Jones LLC boosted its stake in Lam Research by 1,032.4% in the 4th quarter. Brighton Jones LLC now owns 14,189 shares of the semiconductor company’s stock worth $1,025,000 after purchasing an additional 12,936 shares during the period. Golden State Wealth Management LLC boosted its stake in Lam Research by 18.5% in the 1st quarter. Golden State Wealth Management LLC now owns 2,249 shares of the semiconductor company’s stock worth $164,000 after purchasing an additional 351 shares during the period. DAVENPORT & Co LLC boosted its stake in Lam Research by 34.1% in the 1st quarter. DAVENPORT & Co LLC now owns 31,043 shares of the semiconductor company’s stock worth $2,257,000 after purchasing an additional 7,891 shares during the period. Rossby Financial LCC bought a new position in Lam Research in the 1st quarter worth approximately $37,000. Finally, Keybank National Association OH raised its holdings in shares of Lam Research by 8.2% during the 1st quarter. Keybank National Association OH now owns 39,818 shares of the semiconductor company’s stock worth $2,895,000 after acquiring an additional 3,004 shares in the last quarter. 84.61% of the stock is currently owned by institutional investors.

Lam Research Stock Performance

NASDAQ:LRCX opened at $161.01 on Friday. The stock’s fifty day moving average is $127.98 and its 200 day moving average is $102.36. Lam Research Corporation has a fifty-two week low of $56.32 and a fifty-two week high of $165.22. The firm has a market capitalization of $202.23 billion, a PE ratio of 35.46, a PEG ratio of 1.68 and a beta of 1.84. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.60 and a current ratio of 2.21.

Lam Research (NASDAQ:LRCX) last released its quarterly earnings results on Wednesday, October 22nd. The semiconductor company reported $1.26 earnings per share for the quarter, beating the consensus estimate of $1.22 by $0.04. Lam Research had a return on equity of 60.60% and a net margin of 29.66%.The company had revenue of $5.32 billion for the quarter, compared to analyst estimates of $5.23 billion. During the same quarter in the prior year, the firm posted $0.86 EPS. Lam Research’s quarterly revenue was up 27.7% compared to the same quarter last year. Lam Research has set its Q2 2026 guidance at 1.050-1.250 EPS. On average, sell-side analysts anticipate that Lam Research Corporation will post 3.71 earnings per share for the current year.

Lam Research Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, October 15th. Investors of record on Wednesday, September 24th were issued a dividend of $0.26 per share. This represents a $1.04 annualized dividend and a yield of 0.6%. The ex-dividend date was Wednesday, September 24th. This is a boost from Lam Research’s previous quarterly dividend of $0.23. Lam Research’s payout ratio is currently 22.91%.

Insider Buying and Selling at Lam Research

In related news, insider Ava Harter sold 9,010 shares of the stock in a transaction on Monday, October 27th. The stock was sold at an average price of $157.47, for a total transaction of $1,418,804.70. Following the sale, the insider owned 56,786 shares in the company, valued at approximately $8,942,091.42. This represents a 13.69% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, SVP Vahid Vahedi sold 52,190 shares of the stock in a transaction on Monday, October 13th. The stock was sold at an average price of $138.90, for a total value of $7,249,191.00. Following the completion of the sale, the senior vice president owned 251,047 shares in the company, valued at approximately $34,870,428.30. The trade was a 17.21% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.31% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on LRCX shares. Raymond James Financial upped their price objective on Lam Research from $90.00 to $110.00 and gave the stock an “outperform” rating in a report on Thursday, July 31st. New Street Research upped their price objective on Lam Research from $105.00 to $140.00 and gave the stock a “neutral” rating in a report on Thursday, October 23rd. Erste Group Bank started coverage on Lam Research in a report on Thursday, August 14th. They set a “buy” rating on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $170.00 price objective on shares of Lam Research in a report on Thursday, October 23rd. Finally, Summit Insights cut Lam Research from a “buy” rating to a “hold” rating in a report on Thursday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, twenty-six have assigned a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $148.54.

About Lam Research

Lam Research Corporation designs, manufactures, markets, refurbishes, and services semiconductor processing equipment used in the fabrication of integrated circuits. The company offers ALTUS systems to deposit conformal films for tungsten metallization applications; SABRE electrochemical deposition products for copper interconnect transition that offers copper damascene manufacturing; SOLA ultraviolet thermal processing products for film treatments; and VECTOR plasma-enhanced CVD ALD products.